

ISO/TS 16791:2020 (E)

Health informatics — Requirements for international machine-readable coding of medicinal product package identifiers

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms, definitions and abbreviated terms
3.1	Terms and definitions
3.2	Abbreviated terms
4	Procedural background
4.1	General
4.2	Identification
4.3	International machine-readable coding
4.4	Medicinal product
4.5	Labelling
4.6	Package identifier
4.7	Serialization
5	Usage requirements
5.1	General
5.2	Traceability
5.2.1	Principles
5.2.1.1	General
5.2.1.2	Repackaging
5.2.1.3	Compounded preparation
5.2.1.4	Reconstitution
5.2.1.5	BAID — Batch/lot number
5.2.2	Guidelines
5.3	Measures to combat falsification of medicines
5.3.1	Principles
5.3.1.1	General
5.3.1.2	Using serialization
5.3.1.3	First approach — Product authentication
5.3.1.4	Second approach — Supply chain integrity
5.3.2	Guidelines for both approaches
5.3.3	Product authentication
5.3.4	Supply chain integrity
5.4	Improving patient safety at point of care
5.4.1	Principles
5.4.2	Guidelines
5.5	Support of healthcare systems
5.5.1	Principles
5.5.2	Guidelines
5.6	Procurement and stock management
5.6.1	Principles
5.6.2	Guidelines
5.7	Overview of guidelines
6	Economic aspects
6.1	General

- 6.2 **Manufacturer perspective**
- 6.3 **Healthcare provider perspective**
- Annex A (informative) Relationship between PhPID and MPID**
 - A.1 **Introduction**
 - A.2 **Example from ISO 11616**
 - A.3 **Example from openMedicine**
- Annex B (informative) Packaging hierarchy, relationship between MPID, PCID and GTIN®**
 - B.1 **Packaging hierarchy and different GTINs® and attributes**
 - B.2 **Relationship between MPID, PCID and GTIN®**
- Annex C (informative) Identification of trade items and logistic units**
- Annex D (informative) Examples for Package Identifier**
 - D.1 **General**
 - D.2 **PhPID set**
 - D.3 **MPID**
 - D.4 **PCID**
 - D.5 **EMA Centralized**
 - D.6 **(European) National, Mutual Recognition, Decentralized**
 - D.6.1 **For product registered in market where each pack is authorized individually:**
 - D.6.2 **For product registered in a market where all packs are sharing the same authorization:**
 - D.7 **US**
 - D.8 **Japan**
- Annex E (informative) Personalized Medicine**
 - E.1 **General**
 - E.2 **Definition**
 - E.3 **Characteristics and identification needs**
 - E.4 **Possible identification solutions**

Page count: 36